BiomX appoints Susan Blum to board as Class II director and audit committee chair; amends bylaws

BiomX Inc.

Board size increased to eight; Susan Blum appointed as Class II director with term expiring at 2025 annual meeting.
Blum named chair of audit committee and designated audit committee financial expert.
Blum is CFO of Melinta Therapeutics; previously VP Finance & CAO at Melinta, controller at Textura, and director at Orbitz.
Bylaws amended to eliminate requirement that board and committees be comprised of an odd number of directors.
Indemnification agreement entered into with Blum; terms consistent with other directors.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Susan Blum

Class II Director

PHGE · BiomX Inc.

Effective: 2024-04-11
Filed: April 15, 2024, 7:59 PM ET

increased the size of the Board to eight members and appointed Susan Blum to serve as a Class II Director of the Company, with a term expiring at the Company’s annual meeting of stockholders in 2025, in order to fill the resulting vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Blum was appointed as Class II Director at BiomX Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

increased the size of the Board to eight members and appointed Susan Blum to serve as a Class II Director of the Company, with a term expiring at the Company’s annual meeting of stockholders in 2025, in order to fill the resulting vacancy on the Board.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BiomX Inc.: Eliminated requirements that the Board and its committees be comprised of an odd number of directors by amending Sections 1, 2, and 14 of Article II of the Amended and Restated Bylaws (effective 2024-04-11).

Change: bylaw amendment
Effective: 2024-04-11

Exact text from the filing

On April 11, 2024, the Board approved amendments to the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of such date, to eliminate the requirements that the Board and its committees be comprised of an odd number of directors. The Amended Bylaws amend Sections 1, 2 and 14 of Article II of the Amended and Restated Bylaws to delete such requirements.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-033032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.